Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.45 |
| ▸ | MTOR | P42345 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KHK | P50053 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20369843 | 0.82 | ALDH1A1 (0.54) | POLBCRHBPCRHR2ALDH1A1HPGD | |
| SCHEMBL27808801 | 0.81 | GAA (0.53) | POLBPIK3CAMTORALDH1A1HPGD | |
| SCHEMBL20859503 | 0.79 | KDM4E (0.53) | POLBPIK3CAMTORALDH1A1HPGD | |
| SCHEMBL31128249 | 0.79 | POLB (0.47) | POLBALDH1A1HPGDKHKCYP1A2 | |
| SCHEMBL26151191 | 0.79 | TRPM8 (0.52) | POLBPIK3CAMTORALDH1A1HPGD | |
| SCHEMBL22122604 | 0.77 | PIK3CA (0.42) | PIK3CAMTORNOS3NOS1NOS2 | |
| SCHEMBL21698767 | 0.76 | NCF1 (0.48) | POLBNUDT1CRHBPCRHR2PIK3CA | |
| SCHEMBL16021154 | 0.76 | KDM4E (0.46) | POLBPIK3CAALDH1A1HPGDKHK | |
| SCHEMBL18072393 | 0.75 | PIK3CA (0.54) | NUDT1CRHBPCRHR2PIK3CAMTOR | |
| SCHEMBL19548102 | 0.71 | NUDT1 (0.63) | POLBNUDT1CRHBPCRHR2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12391709-B2 | Inhibitors of KIF18A and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4572855-A1 | INHIBITORS OF KIF18A AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250197428-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2024039829-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039829-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3897855-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132651-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132651-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073504-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | POLB 328/4885NUDT1 3621/4885CRHBP 3391/4885 |
| US-20250197428-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF2C | POLB 459/4885NUDT1 2443/4885CRHBP 4200/4885 |
| US-12391709-B2 | Inhibitors of KIF18A and uses thereof | KIF18A, KIF18B, KIF2C | POLB 459/4885NUDT1 2443/4885CRHBP 4200/4885 |
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | POLB 328/4885NUDT1 3621/4885CRHBP 3391/4885 |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | POLB 310/4885NUDT1 1446/4885CRHBP 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.